



3 November 2017

Market Announcement Office
Australian Securities Exchange
Level 6, 20 Bridge Street
SYDNEY NSW 2000

Dear Sirs,

**General Information on
Zicom Innovations Group Pte Ltd**

Further to our announcement on the formation of Zicom Innovations Group Pte Ltd, the Group is pleased to release a General Information Leaflet on Zicom Innovations Group Pte Ltd.

Yours faithfully
Zicom Group Limited

G L Sim
Chairman

For personal use only

Zicom Innovations Group

Zicom Innovations Group is an Integrated Medtech Company to be spun off from the Zicom Group Ltd, a 40 year old diversified engineering group that has many decades of regionalization experience with direct presence in key Asia-Pacific markets like China, Australia, Thailand, Malaysia, Indonesia, Philippines, and Bangladesh.

Zicom Innovations focuses on medtech products such as minimally-invasive surgery, diagnostics and healthcare IT. Its core competencies include (i) Product Prototyping, (ii) Clinical Study Coordination, (iii) Large-scale Manufacturing, and (iv) Global Commercialization.


The team comprises of experienced and proactive executives with impeccable leadership and business experience led by Founder and Chairman, Mr GL Sim. In addition, Zicom Innovations is also a MedTech co-investor with SPRING Seeds, and the combined funding pool of S\$30M is used to invest & nurture high growth medtech companies.

Our partners include leading local institutions like A*STAR, National University Hospital (NUH), Singapore General Hospital (SGH), and Singapore National Eye Center (SNEC), as well as renowned overseas institutions like Mayo Clinic, Arup Laboratories, Imperial College Healthcare, Universitätsklinikum Tübingen, Beijing Friendship Hospital, Royal Melbourne Hospital, etc.



Mr Sim Giok Lak
Chairman

- Director of SPRING
- Chairman, Growth Policy Advisory Committee, SPRING
- Chairman, Grant Appeal Panel, SPRING
- Member, Strategic Advisory Panel, DxD Hub
- Member, Singapore National Eye Center Incubation Board
- Board of Governors, UOB-SMU Asian Enterprise Institute
- E&Y Entrepreneur 2008 (Industrial)




Corporate & Commercialization
(see reverse side for more info)

Engineering & Manufacturing
(see below for more info)

Note
*Likely outcome of the group of companies to be spun off under Zicom Innovations Group Pte Ltd. Actual corporate structure may differ.

**Companies invested under SPRING's Co-Investment scheme where Zicom has the option to purchase SPRING's shares at a future date based on an agreed formula

10 Years of Foundation Work to Establish Growing Precision Engineering & MedTech Segment



Key Management

Corporate

Engineering & Manufacturing

Commercialization



Mr Sim Kok Hwee Chief Executive Officer | Mr Sim Kok Yew Deputy Chief Executive Officer | Dr Poon Thong Yuen Chief Investment Officer | Ms Jenny Lim Chief Financial Officer | Ms Sim Hui Shan Vice President Corporate Development | Ms Liew Lai Chee Head Regulatory Affairs | Mr Peter Cheng Chief Technology Officer | Ms Sophia Niam Chief Operations Officer | Dr Tho Lai Leng Chief Commercial Officer (Medical Technologies) | Dr Lim Chee Tiong Vice President Investments & Commercialization | Dr Emril Ali Vice President ANZ Commercialization

Our Infrastructure and Outreach

Market Adoption



- Drive market entry & expansion of products & scout for synergistic technologies that complement our platform via **Market Access and Collaboration Centers (MACCs)**.
- Provide market assessment, technology scouting, clinical partnerships, regulatory guidance, sales channels
- Engaged commercially with various thought leaders and distributors in key markets like Singapore, USA, Europe, and Australia.
- Established an end-to-end sales and after sale support team to focus on expansion into the Asia Pacific region.

Clinical & Regulatory



- Clinical studies with local and overseas academic centers
- Publications in high impact factor journals
- Attained key market regulatory approvals with FDA, CE, HSA, TGA
- Regional markets product registrations
- Post market surveillance

Investments



- Corporate venturing with investments exceeding US\$30M so far into deep technologies
- Co-Investor with Singapore Government Agency, SPRING.



PRC MACC

SGP HUB

ANZ MACC




Engineering & Manufacturing



- Principal Activities**
 - Contract Manufacturing & Automation Engineering
- Customer Segments**
 - Healthcare and Consumer Electronics
- Engineering Capabilities**
 - Electromechanical, mechanical, electrical, software, firmware, optics, photonics, medical imaging, DICOM, medical data analytics, quality, manufacturing
- Facilities in Asia**
 - Approx. 100,000 square feet situated at Woodlands & Batam
- Quality Certifications**
 - ISO 13485:2003, ISO 9001:2008, FDA 21 CFR Part 211






Product Description

- Needle-based robotic platform for prostate cancer biopsy and treatment (US\$47B market by 2016)¹

Status update

- Commercialization stage
- Key customers/ collaborators: Singapore General Hospital, Mayo Clinic, NYU Langone Medical Center, Rush Medical, Imperial College Healthcare, Universitätsklinikum Tübingen, Universitätsklinikum Freiburg, Epworth Hospital, Macquarie Uni Hospital




Product Description

- Laser-based imaging platform supporting development and commercialization of fatty liver drugs (US\$25B market by 2026)²

Status update

- Commercialization stage
- Key customers/ collaborators: Singapore General Hospital, National University Hospital, Arup Laboratories, Queen Elizabeth Uni Hospital, Monash Uni, Royal Melbourne Hospital, Beijing Friendship Hospital, Guangzhou Southern Medical Uni Hospital, Taiwan Uni Hospital




Product Description

- Cloud-based Eye disease grading platform to allow prevention or early treatment of avoidable blindness such as glaucoma (US\$2.4B market in 2013)⁽³⁾

Status update

- Commercialization stage
- Key customers/ collaborators: Singapore National Healthcare Group & SNEC, Topcon, NGOs like Sightsavers and Operation Eyesight Universal



Product Description

- Blood diagnostic platform that enhances performance of assays performed using flow cytometer (US\$5.7B market by 2018)⁽⁴⁾

Status update

- Commercialization stage
- Key customers/ collaborators: GSK, Merck, Novartis, Takeda, AstraZeneca, Genentech, Charles River




Product Description

- Laser-based eye surgical tool that provides rapid treatment for glaucoma (US\$2.4B market in 2013)⁽⁵⁾

Status update

- Clinical trial stage
- Key collaborators: Meir Medical Center (Israel), Sheba Medical Center (Israel)



Product Description

- Endoscopic probe for realtime diagnosis of gastrointestinal diseases (US\$30B market in 2015)⁽⁶⁾

Status update

- Clinical trial stage
- Key collaborators: National University Hospital, National University of Singapore

¹ BCC Research, Mar 2017: Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

² Global Data, May 2017: Nash – Opportunity Analysis and Forecasts to 2026

³ <https://www.ddmag.com/article/2015/06/glaucoma-treatment-market-value-will-grow-moderately-3b-2023>

⁴ BCC Research, Oct 2013: Flow Cytometry – Products, Technologies and Global Markets

⁵ Zion Market Research, Oct 2016: Global Endoscopy Devices Market Set for Rapid Growth to Reach USD 41,813.42 million in 2021